Phase 2/3 Study of Monotherapy LY2157299 Monohydrate in Very Low-, Low-, and Intermediate-Risk Patients With Myelodysplastic Syndromes
Phase of Trial: Phase II/III
Latest Information Update: 11 Mar 2019
Price : $35 *
At a glance
- Drugs Galunisertib (Primary)
- Indications Myelodysplastic syndromes
- Focus Proof of concept; Therapeutic Use
- Sponsors Eli Lilly and Company
- 12 Oct 2017 Status changed from active, no longer recruiting to completed.
- 12 Jul 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2017.
- 11 Apr 2017 Planned End Date changed from 1 Mar 2017 to 1 Sep 2017.